Generate Biomedicines, Inc. (GENB) SEC Filings & Earnings Calls
EquiReason read 5 Generate Biomedicines, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-08-26 — Generate Biomedicines presented Phase 1 data for GB-0895 (anti-TSLP mAb) showing well-tolerated safety, ~98-day half-life, and sustained biomarker suppression for at least 6 months.
Source: SEC EDGAR filings · read by EquiReason
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
26 Aug 20268-K · 7.01Generate Biomedicines presented Phase 1 data for GB-0895 (anti-TSLP mAb) showing well-tolerated safety, ~98-day half-life, and sustained biomarker suppression for at least 6 months in asthma patients.open
Figures in the filing · each found in the filing text
| half-life | $98.00 |
Risks flagged
Phase 1 data only; Phase 3 trials ongoing and results may differ.
“GB-0895 is being evaluated in two ongoing Phase 3 ... studies” · word for word
6 Aug 20268-K · 2.02Generate Biomedicines reported Q2 2026 results: net loss widened to $67.3M from $56.7M YoY; cash burn $138.3M in H1; R&D expenses increased; Phase 3 SOLAIRIA studies advancing; Novartis advanced platform-designed biologic to preclinical pipearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents, and marketable securities · 2026-06-30 | $457M | |
| Revenue · Q2-2026 | $6M | -38% y/y |
| Research and development expenses · Q2-2026 | $64M | +8% y/y |
| Net loss · Q2-2026 | $67M | +19% y/y |
| Net cash used in operating activities · H1-2026 | $138M | +36% y/y |
Risks flagged
Accelerating cash burn rate; additional capital required for long-term operations.
“Net cash used in operating activities was $138.3 million for the six months ended June 30, 2026, compared with $101.9 million for the six months ended June 30, 2025.” · word for word
Revenue decline from collaboration programs; dependence on partnership milestones.
“Revenue for the quarter ended June 30, 2026, was $6.3 million, compared with $10.1 million for the same period in 2025.” · word for word
6 Aug 202610-QGenerate Biomedicines reported Q2 2026 results with net loss of $67.3M and collaboration revenue of $6.3M, reflecting ongoing R&D investment and IPO completion.earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q2-2026 | $457M | |
| Net loss · H1-2026 | $-129M | +28% y/y |
| Collaboration revenue · H1-2026 | $14M | -29% y/y |
| Research and development expense · H1-2026 | $122M | +15% y/y |
| Accumulated deficit · Q2-2026 | $-805M | +19% y/y |
| Net loss per share, basic and diluted · H1-2026 | $-1.41 | -61% y/y |
| Operating cash flow · H1-2026 | $-138M | +36% y/y |
Risks flagged
Clinical-stage company with no approved products
“We are a clinical-stage biotechnology company with a limited operating history and no products approved by regulators for commercial sale, which may make it difficult to evaluate our current and future business prospects.” · word for word
Substantial additional capital required
“We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate programs, product candidates (including clinical trials), investments in The Generate Platform or future commercialization efforts.” · word for word
Dependence on unproven AI platform
“Our approach to the engineering and development of our programs is unproven, and we may not be successful in our efforts to identify and develop any programs and product candidates of commercial value by leveraging The Generate Platform.” · word for word
7 May 20268-K · 2.02Generate Biomedicines reported Q1 2026 financial results; cash $516.6M post-IPO; revenue $7.2M; net loss $61.7M; pipeline progress on GB-0895, GB-4362, GB-5267.earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents, and marketable securities · Q1-2026 | $517M | +133% y/y |
| Revenue · Q1-2026 | $7M | -18% y/y |
| Research and development expenses · Q1-2026 | $58M | +24% y/y |
| General and administrative expenses · Q1-2026 | $14M | +34% y/y |
| Net loss · Q1-2026 | $-62M | +39% y/y |
| Net cash used in operating activities · Q1-2026 | $-80M | +51% y/y |
Risks flagged
Clinical-stage biotech with no approved products; reliance on pipeline success.
“Clinical-stage generative biology company; no revenue from product sales.”
Increasing net loss and cash burn; expects to require additional capital.
“Net loss $61.7M; operating cash burn $80.4M; expects to require additional capital.”
7 May 202610-QQ1 2026 results: net loss of $61.7M, collaboration revenue of $7.2M, IPO proceeds of $369.3M extended cash runway into first half of 2028earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q1-2026 | $517M | |
| Net loss · Q1-2026 | $62M | |
| Accumulated deficit · Q1-2026 | $738M | |
| Collaboration revenue · Q1-2026 | $7M | |
| Research and development expense · Q1-2026 | $58M | |
| General and administrative expense · Q1-2026 | $14M | |
| Net loss per share, basic and diluted · Q1-2026 | $1.07 | |
| Weighted average common shares outstanding, basic and diluted · Q1-2026 | 64,871,295 |
Risks flagged
Clinical-stage biotech with no approved products
“We are a clinical-stage biotechnology company with a limited operating history and no products approved by regulators for commercial sale” · word for word
Dependence on AI platform unproven for commercial value
“Our approach to the engineering and development of our programs is unproven, and we may not be successful in our efforts to identify and develop any programs and product candidates of commercial value by leveraging our Generate Platform.” · word for word
Substantial additional capital required
“We will require substantial additional capital to finance our operations in the future.” · word for word
Generate Biomedicines, Inc. — questions
- What did Generate Biomedicines, Inc. file recently?
- 5 SEC filings in the last 12 months. Latest: 8-K on 2026-08-26 — Generate Biomedicines presented Phase 1 data for GB-0895 (anti-TSLP mAb) showing well-tolerated safety, ~98-day half-life, and sustained biomarker suppression for at least 6 months in asthma patients.
Every figure on this page comes from Generate Biomedicines, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.